|
TW202039000A
|
|
Combination hbv therapy
|
|
TW202039547A
|
|
Antibodies that neutralize hepatitis b virus and uses thereof
|
|
CA3105222A1
|
|
Antibodies against campylobacter species
|
|
WO2020221450A1
|
|
Antibodies and methods for treatment of influenza a infection
|
|
WO2020221451A1
|
|
Antibodies binding to plasmodium circumsporozoite protein and uses thereof
|
|
WO2020078568A1
|
|
Antibodies and methods for treatment of lyssavirus infection
|
|
WO2019042555A1
|
|
Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
|
|
US2019256582A1
|
|
Novel antibodies specifically binding to zika virus epitopes and uses thereof
|
|
CN107428819A
|
|
Strongly neutralize rabies viruses and the antibody and its purposes of other Lyssaviruses virus
|
|
WO2017059878A1
|
|
Antibodies that potently neutralize hepatitis b virus and uses thereof
|
|
CA2924559A1
|
|
Neutralizing anti-influenza a antibodies and uses thereof
|
|
WO2015010792A1
|
|
Antibodies that potently neutralize rsv and uses thereof
|
|
WO2014110092A1
|
|
Methods of generating robust passive and active immune responses
|
|
NZ630920A
|
|
Antibodies that neutralize rsv, mpv and pvm and uses thereof
|
